Back HIV/AIDS

HIV / AIDS

PrEP Rally: As Numbers Rise, Advocates Want Wider Access

The number of people using pre-exposure prophylaxis, or PrEP, to prevent HIV infection has risen steadily over the past year, according to data presented this week at a San Francisco community engagement forum. But PrEP advocates -- including 3 city supervisors -- say more needs to be done to overcome barriers to access for all who want it.

alt

ICAAC 2014: Cobicistat Long-term Efficacy Matches Ritonavir as PI Booster

Long-term rates of viral suppression and side effects were similar among people using cobicistat and those using ritonavir as a booster for atazanavir (Reyataz), according to 3-year data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. Another study found that cobicistat was well-tolerated by people with mild-to-moderate kidney impairment.

alt

September 18 is National HIV/AIDS and Aging Awareness Day

This Thursday, September 18, is the 7th annual National HIV/AIDS and Aging Awareness Day (NHAAAD), an occasion to focus on the challenges facing the aging population regarding HIV prevention, testing, care, and treatment, as well as overall health and wellbeing for the growing population of older people living with HIV.

alt

ICAAC 2014: Tenofovir Vaginal Ring and Nanoparticle Gel Are Protective in Animal Studies

A vaginal ring that dispenses tenofovir protected all 6 macaque monkeys exposed to an HIV-like virus, while a heat-sensitive vaginal gel containing tenofovir nanoparticles prevented infection of mice, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.

alt

ICAAC 2014: New Drug Isavuconazole Is Effective Against Opportunistic Fungal Infections

A new antifungal drug, isavuconazole, matched the efficacy of voriconazole for treatment of invasive fungal infections in cancer patients with compromised immunity, but with fewer side effects, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.Isavuconazole was shown to be effective against various fungal infections that act as opportunistic illnesses in people with HIV/AIDS, including Aspergillus, Candida, and Cryptococcus.

alt

PrEP by the Numbers: Interpreting Conflicting Study Data

A recent ad campaign from the AIDS Healthcare Foundation has kicked of a new round of controversy about HIV pre-exposure prophylaxis (PrEP) and how to interpret apparently conflicting numbers from prevention studies.

alt

NIH Awards Grant for Vaginal Ring for HIV Prevention

The National Institutes of Health has awarded a $20 million grant to a consortium that will seek to develop an intravaginal ring that delivers antiretroviral drugs for prevention of HIV infection, the participating research institutions recently announced. The collaboration will test various combinations of antiretrovirals to determine which are most effective when delivered together for pre-exposure prophylaxis, or PrEP.

alt